MODULE – 10

Dr. Vishal Patil discussed a rare case of a 49-year-old male with vitiligo secondary to discoid lupus erythematosus (DLE), presenting with a two-month history of erythema and depigmented patches on the hands, ears, and face. Initial treatment with oral hydroxychloroquine and topical tacrolimus showed no clinical improvement.
...Read MoreBoth conditions were linked via the JAK-STAT signaling pathway causing autoimmune melanocyte destruction, leading to a revised treatment with tofacitinib 5 mg twice daily, a JAK1/JAK3 inhibitor. Within one month, lesions flattened with visible perivascular repigmentation and no new lesions. After one year, the patient achieved approximately 75% repigmentation of vitiligo patches along with complete regression of DLE symptoms. The doctor emphasized that this rare co-occurrence remains a therapeutic challenge, and the case highlights the effectiveness of JAK inhibitors in managing resistant dermatological conditions by targeting specific pathways.